Cost-consequence of abatacept as first-line therapy in Japanese rheumatoid arthritis patients using IORRA real-world data.
PLoS One
; 17(11): e0277566, 2022.
Article
in En
| MEDLINE
| ID: mdl-36383610
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Arthritis, Rheumatoid
/
Antirheumatic Agents
Type of study:
Health_economic_evaluation
/
Prognostic_studies
Limits:
Aged
/
Humans
Country/Region as subject:
America do norte
/
Asia
Language:
En
Journal:
PLoS One
Journal subject:
CIENCIA
/
MEDICINA
Year:
2022
Document type:
Article
Affiliation country:
Country of publication: